Documentation Required for an Ozempic Gastroparesis Injury Claim

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Exposure Concerns

For decades, general health and science information has served as the foundation for public understanding of medication benefits and risks. This legacy context emphasized broad wellness principles and the importance of informed patient-provider communication. Within this framework, discussions of prescription drugs naturally focused on therapeutic efficacy and common side effects, establishing a baseline of health literacy that empowered individuals to make educated decisions. As this informational heritage evolved, it became increasingly clear that certain medications require more specialized scrutiny regarding their long-term impact on bodily systems. The transition from general health awareness to specific exposure concerns emerges naturally when considering the widespread use of GLP-1 receptor agonists in modern medicine. These agents, originally developed for metabolic regulation, have seen expanded utilization across diverse patient populations. This shift in prescribing patterns necessitates a corresponding evolution in how we document and evaluate potential adverse outcomes. The occupational exposure concern here is not limited to healthcare workers handling these compounds, but extends to patients who experience sustained pharmacological exposure through prescribed regimens. Understanding the full spectrum of documentation required for injury claims—including medical records, prescription histories, and symptom timelines—becomes paramount when moving from general health education to the specific context of medication-associated complications. This documentation framework bridges the gap between population-level health information and individual exposure scenarios.

Find Out If You Qualify for Compensation →

Clinical Evidence of Gastroparesis and Pharmacological Link to Ozempic

The documentation required to support an Ozempic gastroparesis injury claim centers on three pillars: clinical evidence of gastroparesis, pharmacological evidence linking Ozempic to gastrointestinal harm, and proof of inadequate warnings. Each pillar must be substantiated with specific medical records, adverse-event reports, and regulatory data. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Its clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, bloating, and upper abdominal pain. Diagnosis is typically confirmed via gastric emptying scintigraphy, breath tests, or wireless motility capsule studies, showing delayed emptying of solid food. For an injury claim, a physician must document these symptoms and diagnostic findings, establishing that the patient meets established criteria for gastroparesis. The claim should include records of symptom onset, duration, and severity, as well as exclusion of other causes such as diabetes, prior surgery, or medication-induced gastroparesis. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes. GLP-1 agonists slow gastric emptying as part of their mechanism, which can lead to gastrointestinal adverse reactions. According to the FDA-approved labeling, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data demonstrate a clear dose-response relationship and higher incidence of gastrointestinal issues with Ozempic.

Mechanistic Pathways and Inadequate Warnings

The mechanistic link between Ozempic and gastroparesis is well-established. GLP-1 receptors are expressed on gastric smooth muscle and enteric neurons. Activation of these receptors delays gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended for glycemic control but can become pathological, leading to symptomatic gastroparesis. The FDA Adverse Event Reporting System (FAERS) data further support this link: among the most frequently reported adverse events for Ozempic are nausea (8652 reports), vomiting (5578 reports), and impaired gastric emptying (2693 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). The presence of "impaired gastric emptying" as a distinct reported term indicates that clinicians and patients are identifying this specific harm. For a claim, a medical expert should opine that the patient's gastroparesis is consistent with known GLP-1 agonist effects and that the temporal relationship supports causation. The adequacy of warnings is a critical risk anchor. The Ozempic label lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct, serious adverse event. The label mentions "gastritis" and "gastroesophageal reflux disease" but not "gastroparesis" or "impaired gastric emptying" as a warning. The FAERS data show 2693 reports of impaired gastric emptying, suggesting a signal that may warrant stronger labeling. For an attorney, this gap in warnings can support a claim that the manufacturer failed to adequately communicate the risk of gastroparesis to prescribers and patients. Documentation for this pillar includes the label itself, FAERS data, and expert testimony on the standard of care for drug warnings.

Attorney Considerations and Timeline Documentation

For patients pursuing a claim, key considerations include statute of limitations, which varies by state, and the need to preserve all medical records, pharmacy records, and correspondence with healthcare providers. The timeline between exposure and documented harm is crucial: the claim should show that gastroparesis symptoms began after starting Ozempic and that other causes were ruled out. The FAERS data can be used to demonstrate that the adverse event is known and reported. Attorneys should also consider whether the patient experienced severe outcomes such as hospitalization, malnutrition, or need for interventions like gastric pacemakers or feeding tubes, which strengthen the claim for damages. A clear timeline must be established. The Ozempic label notes that gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis can develop at any time during treatment. The claim should include dates of Ozempic initiation, dose changes, onset of symptoms, diagnostic tests confirming gastroparesis, and any discontinuation of the drug. Improvement after discontinuation (dechallenge) and recurrence upon rechallenge, if applicable, further support causation. Medical records should document the temporal sequence.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What medical records are needed to prove gastroparesis caused by Ozempic?

You need records documenting symptoms (nausea, vomiting, early satiety, bloating), diagnostic test results (gastric emptying scintigraphy, breath tests, or wireless motility capsule), and physician notes confirming gastroparesis. Also include records ruling out other causes like diabetes or prior surgery. The timeline of symptom onset after starting Ozempic is critical.

How can FAERS data support an Ozempic gastroparesis claim?

FAERS data shows 2693 reports of impaired gastric emptying for Ozempic (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This demonstrates that the adverse event is known and reported, supporting causation and the argument that warnings were inadequate.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.